Does UnitedHealthcare Cover Zetia (Ezetimibe)?

UnitedHealthcare Formulary Placement for Ezetimibe in 2026

Generic ezetimibe appears on most UnitedHealthcare commercial formularies as a Tier 1 or Tier 2 preferred generic, meaning the lowest copay bracket your plan offers. Brand Zetia, by contrast, lands at Tier 3 on the preferred brand tier with prior authorization attached. The distinction matters because Tier 3 copays on UnitedHealthcare plans commonly range from $40 to $75 per fill.

UnitedHealthcare updates its formulary annually, and mid-year changes can shift tier placement. Always verify your specific plan's drug list through the UnitedHealthcare pharmacy benefits portal or by calling the member services number on the back of your card. Employer-sponsored plans, individual marketplace plans, and UnitedHealthcare Medicare Advantage (AARP-branded) plans each maintain separate formularies. A drug that sits at Tier 1 on a large-employer PPO may land at Tier 2 on a marketplace silver plan.

The practical difference for most patients: your prescriber writes for "ezetimibe 10 mg" (the only available dose), the pharmacy dispenses the generic, and UnitedHealthcare processes it at the preferred generic tier with no prior authorization. If your prescriber specifically writes "Zetia, dispense as written," expect the Tier 3 copay and a possible PA requirement. The FDA-approved prescribing information for ezetimibe confirms 10 mg daily as the standard dose for all approved indications [1].

Prior Authorization Criteria for Zetia on UnitedHealthcare

UnitedHealthcare applies prior authorization to brand Zetia on commercial plans but generally does not require PA for generic ezetimibe prescribed as adjunctive therapy with a statin. The PA process is rated moderate difficulty, meaning approvals are common but not automatic.

To meet UnitedHealthcare's typical PA criteria for brand Zetia, your prescriber must document three things. First, a diagnosis of primary hyperlipidemia or homozygous familial hypercholesterolemia (HoFH). Second, an adequate trial of at least one statin, or documented statin intolerance with clinical notes. Third, a clinical reason why brand Zetia is medically necessary over the generic equivalent. That third requirement is the sticking point. Because generic ezetimibe is bioequivalent to brand Zetia, UnitedHealthcare rarely approves brand coverage unless the patient has a documented allergy to a specific inactive ingredient in the generic formulation.

For ezetimibe monotherapy (without a concurrent statin), some UnitedHealthcare plans require documentation of statin intolerance. The 2018 AHA/ACC Cholesterol Clinical Practice Guideline recommends ezetimibe as the first add-on for patients who do not reach sufficient LDL-C reduction on maximally tolerated statin therapy [2]. UnitedHealthcare's PA criteria generally align with this guideline framework.

PA turnaround for standard requests is 72 hours. Urgent requests tied to hospital discharge or acute coronary events receive 24-hour review per federal parity requirements.

Step Therapy Requirements

UnitedHealthcare applies step therapy protocols to ezetimibe monotherapy on several commercial plan designs. The logic is straightforward: statins are first-line therapy for LDL-C reduction per every major guideline, so the insurer wants documentation that a statin was tried before approving a non-statin agent as standalone treatment.

Step therapy does not apply when ezetimibe is prescribed alongside a statin. If your prescriber sends in a prescription for ezetimibe 10 mg and you already have an active statin claim in your pharmacy history, UnitedHealthcare's automated system typically approves without intervention. The step therapy gate activates when ezetimibe appears as the sole lipid-lowering agent on file.

To satisfy the step therapy requirement, your prescriber's office needs to submit documentation showing one of the following: a 90-day trial of at least one moderate-to-high-intensity statin (atorvastatin 40 to 80 mg, rosuvastatin 20 to 40 mg, or equivalent), documented intolerance to two or more statins with specific adverse effects noted, or a contraindication such as active liver disease or drug interaction risk. The IMPROVE-IT trial (N=18,144) established that adding ezetimibe to simvastatin 40 mg reduced the primary composite cardiovascular endpoint from 34.7% to 32.7% over a median 6 years of follow-up (absolute risk reduction 2.0%, NNT=50) [3]. This trial's data supports ezetimibe's role as add-on therapy, which is the pathway with the fewest insurance barriers.

How to Appeal a UnitedHealthcare Denial for Zetia

If UnitedHealthcare denies coverage for ezetimibe or brand Zetia, you have a structured appeal pathway. UnitedHealthcare uses a two-level internal appeal process followed by an external review option through an independent review organization (IRO).

Level 1 internal appeal. You or your prescriber must file within 180 days of the denial. Submit a written request to the address on your Explanation of Benefits (EOB) letter. Include the denial reference number, a letter of medical necessity from your prescriber, relevant lab results (LDL-C levels before and after statin therapy), documentation of statin intolerance if applicable, and the specific clinical rationale for ezetimibe. UnitedHealthcare must respond within 30 days for standard appeals or 72 hours for urgent/expedited appeals.

Level 2 internal appeal. If Level 1 is denied, you can escalate. The same documentation requirements apply, but a different reviewer examines the case. Include any new clinical information, such as updated lipid panels or specialist notes. Response timeline: 30 days standard, 72 hours urgent.

External IRO review. After exhausting both internal levels, you can request an external review. An independent physician not affiliated with UnitedHealthcare evaluates the medical necessity determination. The Employee Benefits Security Administration governs external review rights for employer-sponsored plans, while state insurance departments oversee individual market plans. External review decisions are binding on UnitedHealthcare.

A 2022 analysis published in the Journal of the American Medical Association found that patients who pursued external review of insurance denials for prescription drugs won reversal in approximately 45% of cases [4]. Filing an appeal is worth the effort.

Your prescriber's office handles most of the documentation burden. Call the office and specifically request they submit a peer-to-peer review, where your doctor speaks directly with UnitedHealthcare's reviewing physician. Peer-to-peer conversations overturn denials more frequently than paper appeals alone.

Generic Ezetimibe vs. Brand Zetia: Cost Comparison on UnitedHealthcare

The cost gap between generic ezetimibe and brand Zetia is substantial, and UnitedHealthcare's formulary design reflects it. Brand Zetia carries a manufacturer list price of approximately $380 per month. Generic ezetimibe costs roughly $15 per month at cash-pay prices, and UnitedHealthcare's negotiated rate brings insured copays even lower on most plans.

Here is what patients typically pay on UnitedHealthcare commercial plans:

Generic ezetimibe at Tier 1 or Tier 2 runs $3 to $25 per month depending on plan design. Brand Zetia at Tier 3 with PA approval costs $40 to $75 per month in copays, or 25% to 40% coinsurance on plans that use percentage-based cost sharing. Without PA approval, brand Zetia is not covered and the full list price applies.

For patients on UnitedHealthcare Medicare Advantage plans, generic ezetimibe falls into the preferred generic tier with copays typically between $0 and $10. The Centers for Medicare & Medicaid Services requires Medicare Part D plans to cover at least two drugs in each pharmacologic class, and ezetimibe's class (cholesterol absorption inhibitors) is well represented on standard formularies [5].

A practical cost-saving approach: always ask your pharmacy to fill generic ezetimibe. If your prescriber writes "Zetia" on the prescription, most states allow automatic generic substitution unless the prescriber explicitly marks "dispense as written." Confirming generic dispensing at the pharmacy counter can save you $50 or more per fill.

Clinical Evidence Supporting Ezetimibe Coverage

UnitedHealthcare's coverage of ezetimibe rests on a solid evidence base. The drug earned FDA approval in 2002 for primary hyperlipidemia and homozygous sitosterolemia, and a 2004 supplemental approval added the combination with statins for mixed hyperlipidemia [1].

The landmark evidence came from the IMPROVE-IT trial, published in the New England Journal of Medicine in 2015. This trial randomized 18,144 patients who had been hospitalized for acute coronary syndrome within the prior 10 days to either simvastatin 40 mg plus ezetimibe 10 mg or simvastatin 40 mg plus placebo. At a median follow-up of 6 years, the combination group achieved a mean LDL-C of 53.7 mg/dL compared to 69.5 mg/dL in the simvastatin-only group. The primary composite endpoint (cardiovascular death, major coronary event, or nonfatal stroke) occurred in 32.7% of the combination group versus 34.7% of the monotherapy group (hazard ratio 0.936 to 95% CI 0.89 to 0.99, P=0.016) [3].

The 2018 AHA/ACC guideline specifically recommends ezetimibe as the preferred first add-on for patients on maximally tolerated statin therapy who need additional LDL-C lowering before considering PCSK9 inhibitors [2]. This guideline hierarchy is important for insurance purposes: ezetimibe occupies a well-established step in the treatment ladder, making coverage denials harder for insurers to justify.

A 2017 meta-analysis in The Lancet by the Cholesterol Treatment Trialists' Collaboration analyzed individual patient data from 21 trials and found that each 1 mmol/L (38.7 mg/dL) reduction in LDL-C reduced major vascular events by approximately 22%, regardless of whether the reduction came from statins, ezetimibe, or PCSK9 inhibitors [6]. The consistency of benefit across drug classes reinforces ezetimibe's value and its inclusion on insurance formularies.

Dr. Robert Giugliano, the IMPROVE-IT trial co-principal investigator, stated in the NEJM publication: "These findings support the concept that LDL cholesterol lowering with a non-statin agent, when added to statin therapy, incrementally reduces cardiovascular events" [3].

Who Should Request Ezetimibe Through UnitedHealthcare

Not every patient with high cholesterol needs ezetimibe. The drug fills specific clinical roles that map directly to insurance approval criteria.

Patients already on a maximally tolerated statin who remain above their LDL-C goal represent the most straightforward approval pathway on UnitedHealthcare. The 2018 AHA/ACC guideline defines treatment thresholds by risk category: LDL-C ≥70 mg/dL for very high-risk ASCVD patients, ≥100 mg/dL for high-risk primary prevention patients with diabetes or 10-year ASCVD risk ≥20% [2]. If your LDL-C exceeds the target despite 8 to 12 weeks on a high-intensity statin, ezetimibe is the guideline-recommended next step.

Patients with documented statin intolerance form the second major group. True statin intolerance, defined as inability to tolerate two or more statins at any dose due to myalgia, elevated CK levels, or hepatotoxicity, qualifies patients for ezetimibe monotherapy on most UnitedHealthcare plans. A 2015 analysis in the European Heart Journal estimated that 7% to 29% of statin-treated patients report muscle symptoms, though objective statin intolerance confirmed by rechallenge is closer to 5% to 7% [7].

Patients with homozygous familial hypercholesterolemia (HoFH) have an explicit FDA-approved indication for ezetimibe, and UnitedHealthcare covers the drug without step therapy for this diagnosis. HoFH affects approximately 1 in 250,000 people, and these patients typically require multiple lipid-lowering agents simultaneously [1].

Patients taking ezetimibe for weight loss will not receive coverage. Ezetimibe has no FDA-approved indication for weight management, and UnitedHealthcare's utilization management criteria specifically exclude off-label weight loss prescribing from coverage.

Using Manufacturer Savings Cards with UnitedHealthcare

Merck, the manufacturer of brand Zetia, has historically offered copay savings cards that reduce out-of-pocket costs for commercially insured patients. These cards typically cap the patient's copay at $25 to $35 per fill. There is a catch.

UnitedHealthcare commercial plans generally accept manufacturer copay cards at network pharmacies, and the card's discount applies at the point of sale. The patient pays the reduced copay, the card covers the difference between that amount and the plan's required copay, and UnitedHealthcare processes the claim normally. The savings card does not count toward your plan's deductible or out-of-pocket maximum on most UnitedHealthcare plan designs.

Savings cards cannot be used with Medicare, Medicaid, Tricare, or other government-funded insurance. This restriction is federal law under the Anti-Kickback Statute, not a UnitedHealthcare-specific policy [5].

For generic ezetimibe, manufacturer savings cards are rarely relevant because the cash price is already low. If your generic copay is $10 to $25, the math rarely justifies switching to brand Zetia with a savings card. One exception: if your UnitedHealthcare plan has a high deductible and you have not met it, paying $15 cash for generic ezetimibe at a discount pharmacy may be cheaper than running it through insurance at the pre-deductible price.

GoodRx, RxSaver, and similar discount platforms show generic ezetimibe 10 mg at $8 to $18 per 30-day supply at most chain pharmacies. These prices do not apply to your insurance deductible or out-of-pocket maximum, but they offer a floor price when insurance processing would cost more.

Filing a UnitedHealthcare Grievance vs. an Appeal

Patients often confuse grievances with appeals. They are different processes with different outcomes. An appeal challenges a specific coverage denial and asks UnitedHealthcare to reverse the decision. A grievance addresses quality of service, processing delays, or policy concerns without requesting a coverage reversal.

If UnitedHealthcare denied your ezetimibe prescription, you want an appeal. File it within 180 days, include clinical documentation, and follow the two-level internal process described above. If UnitedHealthcare approved ezetimibe but the pharmacy still cannot process the claim due to a system error, that is a grievance. Grievances go to UnitedHealthcare's member services department and are resolved within 30 days.

A peer-to-peer review request from your prescriber is neither an appeal nor a grievance. It is an informal clinical conversation that happens before or alongside the formal appeal. Peer-to-peer reviews can resolve PA denials within 24 to 48 hours and are often the fastest path to approval. Ask your prescriber's office to request one as soon as a denial is issued.

The National Association of Insurance Commissioners maintains a consumer assistance database that can help you identify your state's insurance department for external review filing if both internal appeal levels are exhausted [8].